Lycera and MSD Collaborate on Autoimmune Therapies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lycera and MSD Collaborate on Autoimmune Therapies


ePT--the Electronic Newsletter of Pharmaceutical Technology

The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercialising small-molecule therapies for treating a range of autoimmune diseases.

Under the terms of the agreement, Lycera will receive an upfront payment and research funding, and is also eligible to receive more than $300 million in research, development, regulatory and commercialisation milestone payments. MSD will be responsible for clinical development and will have global marketing and commercialisation rights to any products that may be developed. Lycera will be entitled to royalty payments, and development and sales milestones, on global sales from any products resulting from the collaboration.

The collaboration builds on a previous agreement between the two companies, announced in 2011, targeting the retinoic acid related orphan receptor (RORγt), which is a key transcription factor coordinating the differentiation of T-helper 17 cells and the production of highly pro-inflammatory mediators, such as interleukin-17.

In a statement, Rupert Vessey, senior vice president, global scientific strategy, at Merck Research Laboratories, said, “There are substantial unmet medical needs and opportunities in autoimmune disorders, and new targets representing attractive opportunities that we are very pleased to pursue through our new collaboration with Lycera.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here